anmelden
OMX Copenhagen PI
1.259,22
PKT
+24,37
PKT
+1,97
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen PI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.05.24 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 03.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.05.24 | Novo Nordisk Overweight | Barclays Capital | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 02.05.24 | Novo Nordisk Neutral | UBS AG | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 02.05.24 | A.P. Moeller - Maersk A-S (B) Underperform | Bernstein Research | |
| 02.05.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 02.05.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 03.04.24 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 15.12.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 13.12.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 08.11.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. | |
| 03.11.23 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 03.11.23 | A.P. Moeller - Maersk A-S (B) Sell | Goldman Sachs Group Inc. | |
| 03.11.23 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 11.10.23 | A.P. Moeller - Maersk A-S (B) Sell | Deutsche Bank AG | |
| 13.09.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 08.09.23 | Novo Nordisk Overweight | Barclays Capital | |
| 07.09.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.09.23 | Novo Nordisk Sell | UBS AG | |
| 05.09.23 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 05.09.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.09.23 | Novo Nordisk Overweight | Barclays Capital | |
| 30.08.23 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 25.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 21.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 15.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 11.08.23 | Novo Nordisk Sell | UBS AG | |
| 11.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 10.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 10.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 10.08.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 09.08.23 | Novo Nordisk Buy | Deutsche Bank AG | |
| 09.08.23 | Novo Nordisk Sell | UBS AG | |
| 08.08.23 | Novo Nordisk Overweight | Barclays Capital | |
| 08.08.23 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.08.23 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 07.08.23 | A.P. Moeller - Maersk A-S (B) Overweight | JP Morgan Chase & Co. |